Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Lindsey Winer, Francisco I. Macedo, Abdullah Alfawaz, Antonio Sommariva, Giovanni Cecchetto, Holly L. Neville, Mecker G. Möller

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.

Original languageEnglish (US)
JournalJournal of Pediatric Hematology/Oncology
DOIs
StateAccepted/In press - May 31 2018

Fingerprint

Hemangiosarcoma
Pediatrics
Drug Therapy
Neoadjuvant Therapy
Therapeutics
Registries
Population

Keywords

  • abdominal sarcoma
  • HIPEC
  • pediatric sarcoma
  • pelvic angiosarcoma
  • sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. / Winer, Lindsey; Macedo, Francisco I.; Alfawaz, Abdullah; Sommariva, Antonio; Cecchetto, Giovanni; Neville, Holly L.; Möller, Mecker G.

In: Journal of Pediatric Hematology/Oncology, 31.05.2018.

Research output: Contribution to journalArticle

@article{e4688a04ea2d47ebbaeeabb27ec66fe6,
title = "Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy",
abstract = "The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.",
keywords = "abdominal sarcoma, HIPEC, pediatric sarcoma, pelvic angiosarcoma, sarcoma",
author = "Lindsey Winer and Macedo, {Francisco I.} and Abdullah Alfawaz and Antonio Sommariva and Giovanni Cecchetto and Neville, {Holly L.} and M{\"o}ller, {Mecker G.}",
year = "2018",
month = "5",
day = "31",
doi = "10.1097/MPH.0000000000001231",
language = "English (US)",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

AU - Winer, Lindsey

AU - Macedo, Francisco I.

AU - Alfawaz, Abdullah

AU - Sommariva, Antonio

AU - Cecchetto, Giovanni

AU - Neville, Holly L.

AU - Möller, Mecker G.

PY - 2018/5/31

Y1 - 2018/5/31

N2 - The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.

AB - The management of pediatric abdominopelvic angiosarcoma remains unclear due to limited clinical experience. Herein, we presented the first 2 pediatric patients with abdominal angiosarcoma who were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) after neoadjuvant therapy. The first patient is alive with recurrent disease at 1-year follow-up and the second patient remains disease free after 1 year. CRS and HIPEC should be considered as a therapeutic option in the management of pediatric abdominal angiosarcomas. A multi-institutional international shared registry is needed to further evaluate the role of CRS and HIPEC in inducing remission of abdominopelvic angiosarcomas in the pediatric population.

KW - abdominal sarcoma

KW - HIPEC

KW - pediatric sarcoma

KW - pelvic angiosarcoma

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85048255764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048255764&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001231

DO - 10.1097/MPH.0000000000001231

M3 - Article

C2 - 29863582

AN - SCOPUS:85048255764

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

ER -